JPMorgan Downgrades Sanofi (SNY) to EUR 95 from EUR 105

Sanofi (NASDAQ:SNY) is one of the best pharma stocks to invest in. Sanofi (NASDAQ:SNY) was downgraded to Neutral from Overweight by JPMorgan on December 8, with the firm also bringing the price target down to EUR 95 from EUR 105.

The firm told investors that it is adjusting its ratings in the European pharma group to take into account its 2026 outlook. It anticipates pipeline readouts to drive sector performance, albeit if a considerable amount of the concern surrounding the effect of US price pressure on sector earnings dissipates in Q4. The firm thus downgraded the companies in the sector that did not have pipeline readouts in 2026.

In a separate development, Sanofi (NASDAQ:SNY) announced the completion of its acquisition of Vicebio Ltd on December 4, bringing an early-stage combination vaccine candidate for human metapneumovirus (HMPV) and respiratory syncytial virus (RSV), both of which are respiratory viruses.

With Vicebio’s ‘Molecular Clamp’ technology, the acquisition would support the company’s capabilities in vaccine development and design, complementing Sanofi’s (NASDAQ:SNY) position in respiratory vaccines with the acquired vaccine candidate. It allows the company to provide increased patient and physician choice in RSV and HMPV through the addition of a non-mRNA vaccine to its pipeline.

Sanofi (NASDAQ:SNY) researches, produces, and distributes pharmaceutical products. The company’s operations are divided into the Pharmaceuticals, Consumer Healthcare, and Vaccines segments.

While we acknowledge the potential of SNY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.